Skip to main content

Advertisement

SpringerLink
Log in

Role of Insulin Resistance in the Alzheimer's Disease Progression

  • Review
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

Recent studies continue to find evidence linking Type 2 diabetes (T2D) with Alzheimer's disease (AD), the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Insulin resistance or dysfunction of insulin signaling is a universal feature of T2D, the main culprit for altered glucose metabolism and its interdependence on cell death pathways, forming the basis of linking T2D with AD as it may exacerbate Aβ accumulation, tau hyperphosphorylation and devastates glucose transportation, energy metabolism, hippocampal framework and promulgate inflammatory pathways. The current work demonstrates the basic mechanisms of the insulin resistance mediates dysregulation of bioenergetics and progress to AD as a mechanistic link between diabetes mellitus and AD. This work also aimed to provide a potential and feasible zone to succeed in the development of therapies in AD by enhanced hypometabolism and altered insulin signaling.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Nguyen TT, Giau VV, Vo TK (2017) Current advances in transdermal delivery of drugs for Alzheimer's disease. Indian J Pharmacol 49(2):145–154

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Bedse G et al (2015) Aberrant insulin signaling in Alzheimer's disease: current knowledge. Front Neurosci 9:204–204

    PubMed  PubMed Central  Google Scholar 

  3. Correia SC et al (2012) Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation. Brain Res 1441:64–78

    CAS  PubMed  Google Scholar 

  4. Duarte JMN (2015) Metabolic alterations associated to brain dysfunction in diabetes. Aging Dis 6(5):304–321

    PubMed  PubMed Central  Google Scholar 

  5. De Felice FG, Lourenco MV, Ferreira ST (2014) How does brain insulin resistance develop in Alzheimer's disease? Alzheimer's Dement 10(1 Supplement):S26–S32

    Google Scholar 

  6. Gabbouj S et al (2019) Altered insulin signaling in Alzheimer's disease brain - special emphasis on PI3K-Akt pathway. Front Neurosci 13:629–629

    PubMed  PubMed Central  Google Scholar 

  7. Talbot K et al (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122(4):1316–1338

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Van Giau V, An SSA, Hulme JP (2018) Mitochondrial therapeutic interventions in Alzheimer's disease. J Neurol Sci 395:62–70

    PubMed  Google Scholar 

  9. Ghasemi R et al (2013) Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders. Mol Neurobiol 47(3):1045–1065

    CAS  PubMed  Google Scholar 

  10. Nasoohi S, Parveen K, Ishrat T (2018) Metabolic syndrome, brain insulin resistance, and Alzheimer's disease: thioredoxin interacting protein (TXNIP) and inflammasome as core amplifiers. J Alzheimers Dis 66(3):857–885

    CAS  PubMed  Google Scholar 

  11. Martyn JAJ, Kaneki M, Yasuhara S (2008) Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms. Anesthesiology 109(1):137–148

    PubMed  Google Scholar 

  12. Baker LD et al (2011) Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 68(1):51–57

    PubMed  Google Scholar 

  13. Lee S-H et al (2016) Insulin in the nervous system and the mind: functions in metabolism, memory, and mood. Mol Metab 5(8):589–601

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Ferreira LSS et al (2018) Insulin resistance in Alzheimer's disease. Front Neurosci 12:830

    PubMed  PubMed Central  Google Scholar 

  15. Rorbach-Dolata A, Piwowar A (2019) Neurometabolic evidence supporting the hypothesis of increased incidence of type 3 diabetes mellitus in the 21st century. BioMed Res Int 2019:8

    Google Scholar 

  16. Ormazabal V et al (2018) Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 17(1):122

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Weinstein G et al (2019) Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: pooled analysis from 5 cohorts. PLoS ONE 14(2):e0212293

    CAS  PubMed  PubMed Central  Google Scholar 

  18. de la Monte SM (2014) Type 3 diabetes is sporadic Alzheimers disease: mini-review. Eur Neuropsychopharmacol 24(12):1954–1960

    PubMed  PubMed Central  Google Scholar 

  19. Caberlotto L et al (2019) Cross-disease analysis of Alzheimer’s disease and type-2 diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseases. Sci Rep 9(1):3965

    PubMed  PubMed Central  Google Scholar 

  20. Steen E et al (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease–is this type 3 diabetes? J Alzheimers Dis 7(1):63–80

    CAS  PubMed  Google Scholar 

  21. Hubbard SR (2013) The insulin receptor: both a prototypical and atypical receptor tyrosine kinase. Cold Spring Harb Perspect Biol 5(3):a008946

    PubMed  PubMed Central  Google Scholar 

  22. Hubbard SR (1997) Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16(18):5572–5581

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Bosco D et al (2011) Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med 15(9):1807–1821

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Chiu SL, Chen CM, Cline HT (2008) Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron 58(5):708–719

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Lee CC, Huang CC, Hsu KS (2011) Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways. Neuropharmacology 61(4):867–879

    CAS  PubMed  Google Scholar 

  26. Peineau S et al (2007) LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53(5):703–717

    CAS  PubMed  Google Scholar 

  27. Kim SJ, Han Y (2005) Insulin inhibits AMPA-induced neuronal damage via stimulation of protein kinase B (Akt). J Neural Transm (Vienna) 112(2):179–191

    CAS  Google Scholar 

  28. Tomita T (2016) Apoptosis in pancreatic β-islet cells in Type 2 diabetes. Bosn J Basic Med Sci 16(3):162–179

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Frolich L et al (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) 105(4–5):423–438

    CAS  Google Scholar 

  30. Kivipelto M et al (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62(10):1556–1560

    PubMed  Google Scholar 

  31. Razay G, Vreugdenhil A, Wilcock G (2006) Obesity, abdominal obesity and Alzheimer disease. Dement Geriatr Cogn Disord 22(2):173–176

    PubMed  Google Scholar 

  32. Kullmann S et al (2016) Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiol Rev 96(4):1169–1209

    CAS  PubMed  Google Scholar 

  33. Lillioja S et al (1993) Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329(27):1988–1992

    CAS  PubMed  Google Scholar 

  34. Li J et al (2019) Therapeutic mechanisms of herbal medicines against insulin resistance: a review. Front Pharmacol 10:661

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Kapogiannis D et al (2015) Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease. FASEB J 29(2):589–596

    CAS  PubMed  Google Scholar 

  36. Fontaine JF et al (2009) MedlineRanker: flexible ranking of biomedical literature. Nucleic Acids Res 37:W141–W146

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Wang G (2014) Raison d'être of insulin resistance: the adjustable threshold hypothesis. J R Soc 11(101):20140892–20140892

    Google Scholar 

  38. Nisr RB, Affourtit C (2014) Insulin acutely improves mitochondrial function of rat and human skeletal muscle by increasing coupling efficiency of oxidative phosphorylation. Biochim et Biophys Acta 1837(2):270–276

    CAS  Google Scholar 

  39. Sivitz WI, Yorek MA (2010) Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal 12(4):537–577

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Bucht G et al (1983) Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. Acta Med Scand 213(5):387–392

    CAS  PubMed  Google Scholar 

  41. Matioli MNPS, Nitrini R (2015) Mechanisms linking brain insulin resistance to Alzheimer's disease. Dement Neuropsychol 9(2):96–102

    PubMed  PubMed Central  Google Scholar 

  42. Ma QL et al (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 29(28):9078–9089

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Velazquez R et al (2017) Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease. Neurobiol Aging 58:1–13

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Ruiz HH et al (2016) Increased susceptibility to metabolic dysregulation in a mouse model of Alzheimer's disease is associated with impaired hypothalamic insulin signaling and elevated BCAA levels. Alzheimers Dement 12(8):851–861

    PubMed  PubMed Central  Google Scholar 

  45. Long-Smith CM et al (2013) The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromol Med 15(1):102–114

    CAS  Google Scholar 

  46. Bomfim TR et al (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers. J Clin Invest 122(4):1339–1353

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Clarke JR et al (2015) Alzheimer-associated Abeta oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO Mol Med 7(2):190–210

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Biessels GJ, Reagan LP (2015) Hippocampal insulin resistance and cognitive dysfunction. Nat Rev Neurosci 16(11):660–671

    CAS  PubMed  Google Scholar 

  49. Chakrabarti S et al (2015) Metabolic risk factors of sporadic Alzheimer's disease: implications in the pathology, pathogenesis and treatment. Aging Dis 6(4):282–299

    PubMed  PubMed Central  Google Scholar 

  50. de la Monte SM (2012) Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 9(1):35–66

    PubMed  PubMed Central  Google Scholar 

  51. Patterson C et al (2007) General risk factors for dementia: a systematic evidence review. Alzheimers Dement 3(4):341–347

    PubMed  Google Scholar 

  52. Hoyer S, Oesterreich K, Wagner O (1988) Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? J Neurol 235(3):143–148

    CAS  PubMed  Google Scholar 

  53. Lying-Tunell U et al (1981) Cerebral blood flow and metabolic rate of oxygen, glucose, lactate, pyruvate, ketone bodies and amino acids. Acta Neurol Scand 63(6):337–350

    CAS  PubMed  Google Scholar 

  54. Ogawa M et al (1996) Altered energy metabolism in Alzheimer's disease. J Neurol Sci 139(1):78–82

    CAS  PubMed  Google Scholar 

  55. Chen Z, Zhong C (2013) Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 108:21–43

    CAS  PubMed  Google Scholar 

  56. Costantini LC et al (2008) Hypometabolism as a therapeutic target in Alzheimer's disease. BMC Neurosci 9(Suppl 2):S16–S16

    PubMed  PubMed Central  Google Scholar 

  57. Cunnane S et al (2011) Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition 27(1):3–20

    CAS  PubMed  Google Scholar 

  58. Cunnane SC et al (2016) Can ketones help rescue brain fuel supply in later life? Implications for cognitive health during aging and the treatment of Alzheimer's disease. Front Mol Neurosci 9:53–53

    PubMed  PubMed Central  Google Scholar 

  59. Maher PA, Schubert DR (2009) Metabolic links between diabetes and Alzheimer's disease. Expert Rev Neurother 9(5):617–630

    CAS  PubMed  Google Scholar 

  60. Matsuzaki T et al (2010) Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 75(9):764–770

    CAS  PubMed  Google Scholar 

  61. Fukuyama H et al (1994) Altered cerebral energy metabolism in Alzheimer's disease: a PET study. J Nucl Med 35(1):1–6

    CAS  PubMed  Google Scholar 

  62. Folch J et al (2018) The implication of the brain insulin receptor in late onset Alzheimer's disease dementia. Pharmaceuticals (Basel) 11(1):11

    Google Scholar 

  63. Kim EJ et al (2005) Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain 128(Pt 8):1790–1801

    CAS  PubMed  Google Scholar 

  64. Wang Q et al (2019) Insulin resistance and systemic metabolic changes in oral glucose tolerance test in 5340 individuals: an interventional study. BMC Med 17(1):217

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Baranowski BJ, Bott KN, MacPherson REK (2018) Evaluation of neuropathological effects of a high-fat high-sucrose diet in middle-aged male C57BL6/J mice. Physiol Rep 6(11):e13729

    PubMed  PubMed Central  Google Scholar 

  66. Butterfield DA, Halliwell B (2019) Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci 20(3):148–160

    CAS  PubMed  Google Scholar 

  67. Dienel GA (2019) Brain glucose metabolism: integration of energetics with function. Physiol Rev 99(1):949–1045

    CAS  PubMed  Google Scholar 

  68. Liu Y et al (2008) Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 582(2):359–364

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Yoo DY et al (2016) Chronic type 2 diabetes reduces the integrity of the blood-brain barrier by reducing tight junction proteins in the hippocampus. J Vet Med Sci 78(6):957–962

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Prasad S et al (2014) Diabetes mellitus and blood-brain barrier dysfunction: an overview. J Pharmacovigil 2(2):125

    PubMed  PubMed Central  Google Scholar 

  71. Rosales-Corral S et al (2015) Diabetes and Alzheimer disease, two overlapping pathologies with the same background: oxidative stress. Oxid Med Cell Longev 2015:14

    Google Scholar 

  72. Straub RH (2014) Insulin resistance, selfish brain, and selfish immune system: an evolutionarily positively selected program used in chronic inflammatory diseases. Arthr Res Ther 16(Suppl 2):S4–S4

    Google Scholar 

  73. Hemonnot A-L et al (2019) Microglia in Alzheimer disease: well-known targets and new opportunities. Front Aging Neurosci 11:33–41

    Google Scholar 

  74. Erol A (2008) An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. J Alzheimers Dis 13(3):241–253

    CAS  PubMed  Google Scholar 

  75. de la Monte SM (2017) Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer's disease. Drugs 77(1):47–65

    PubMed  PubMed Central  Google Scholar 

  76. Su F, Bai F, Zhang Z (2016) Inflammatory cytokines and Alzheimer's disease: a review from the perspective of genetic polymorphisms. Neurosci Bull 32(5):469–480

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Bagyinszky E et al (2017) Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis. J Neurol Sci 376:242–254

    CAS  PubMed  Google Scholar 

  78. Giau VV et al (2018) Gut microbiota and their neuroinflammatory implications in Alzheimer's disease. Nutrients 10(11):1765

    PubMed Central  Google Scholar 

  79. Ferreira ST et al (2014) Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimers Dement 10(1 Suppl):S76–83

    PubMed  Google Scholar 

  80. Park CR et al (2000) Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav 68(4):509–514

    CAS  PubMed  Google Scholar 

  81. Kandimalla R, Thirumala V, Reddy PH (2017) Is Alzheimer's disease a type 3 diabetes? A critical appraisal. Biochim Biophys Acta Mol Basis Dis 1863(5):1078–1089

    CAS  PubMed  Google Scholar 

  82. Nguyen NH et al (2020) Potential antidiabetic activity of extracts and isolated compound from Adenosma bracteosum (Bonati). Biomolecules 10(2):201

    CAS  PubMed Central  Google Scholar 

  83. de Matos AM, de Macedo MP, Rauter AP (2018) Bridging type 2 diabetes and Alzheimer's disease: assembling the puzzle pieces in the quest for the molecules with therapeutic and preventive potential. Med Res Rev 38(1):261–324

    PubMed  Google Scholar 

  84. Ayaz M et al (2019) Flavonoids as prospective neuroprotectants and their therapeutic propensity in aging associated neurological disorders. Front Aging Neurosci 11:155

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Canhada S et al (2018) Omega-3 fatty acids' supplementation in Alzheimer's disease: a systematic review. Nutr Neurosci 21(8):529–538

    CAS  PubMed  Google Scholar 

  86. Ajith TA (2018) A recent update on the effects of omega-3 fatty acids in Alzheimer's disease. Curr Clin Pharmacol 13(4):252–260

    CAS  PubMed  Google Scholar 

  87. Broom GM, Shaw IC, Rucklidge JJ (2019) The ketogenic diet as a potential treatment and prevention strategy for Alzheimer's disease. Nutrition 60:118–121

    CAS  PubMed  Google Scholar 

  88. Giau VV et al (2015) Role of apolipoprotein E in neurodegenerative diseases. Neuropsychiatr Dis Treat 11:1723–1737

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Frederiksen KS et al (2018) Effects of physical exercise on Alzheimer's disease biomarkers: a systematic review of intervention studies. J Alzheimers Dis 61(1):359–372

    CAS  PubMed  Google Scholar 

  90. De Felice FG et al (2009) Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 106(6):1971–1976

    PubMed  PubMed Central  Google Scholar 

  91. Lourenco MV et al (2013) TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's beta-amyloid oligomers in mice and monkeys. Cell Metab 18(6):831–843

    CAS  PubMed  Google Scholar 

  92. Craft S et al (2003) Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28(6):809–822

    CAS  PubMed  Google Scholar 

  93. Reger MA et al (2008) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 13(3):323–331

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Reger MA et al (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27(3):451–458

    CAS  PubMed  Google Scholar 

  95. Reger MA et al (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70(6):440–448

    CAS  PubMed  Google Scholar 

  96. Benedict C et al (2008) Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab 93(4):1339–1344

    CAS  PubMed  Google Scholar 

  97. Batista AF et al (2018) The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. J Pathol 245(1):85–100

    CAS  PubMed  PubMed Central  Google Scholar 

  98. McClean PL et al (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 31(17):6587–6594

    CAS  PubMed  PubMed Central  Google Scholar 

  99. McClean PL, Holscher C (2014) Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 76(Pt A):57–67

    CAS  PubMed  Google Scholar 

  100. Perry T et al (2002) Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302(3):881–888

    CAS  PubMed  Google Scholar 

  101. Escribano L et al (2010) Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35(7):1593–1604

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Author notes

  1. Thuy Trang Nguyen and Qui Thanh Hoai Ta have contributed equally to this work.

Authors and Affiliations

  1. Faculty of Pharmacy, Ho Chi Minh City University of Technology (HUTECH), Ho Chi Minh City, 700000, Vietnam

    Thuy Trang Nguyen

  2. Institute of Research and Development, Duy Tan University, Da Nang, 550000, Vietnam

    Qui Thanh Hoai Ta

  3. Faculty of Environmental and Food Engineering, Nguyen Tat Thanh University, Ho Chi Minh City, 700000, Vietnam

    Thi Thuy Dung Nguyen

  4. Faculty of Biotechnology, Ho Chi Minh City University of Food Industry, Ho Chi Minh City, 700000, Vietnam

    Thi Thuy Le

  5. Bionanotechnology Research Group, Ton Duc Thang University, Ho Chi Minh City, 700000, Vietnam

    Van Giau Vo

  6. Faculty of Pharmacy, Ton Duc Thang University, Ho Chi Minh City, 700000, Vietnam

    Van Giau Vo

Authors
  1. Thuy Trang Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qui Thanh Hoai Ta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thi Thuy Dung Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thi Thuy Le
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Van Giau Vo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Van Giau Vo.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nguyen, T.T., Ta, Q.T.H., Nguyen, T.T.D. et al. Role of Insulin Resistance in the Alzheimer's Disease Progression. Neurochem Res 45, 1481–1491 (2020). https://doi.org/10.1007/s11064-020-03031-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-020-03031-0

Keywords

Search

Navigation